Browsing Tag
Hong Kong Stock Exchange
18 posts
China Resources Power stock slips as renewable unit targets record Shenzhen IPO
Read how China Resources New Energy’s $3.62bn Shenzhen IPO could reshape 0836HK stock sentiment, China wind and solar funding.
ENN Natural Gas takeover failure leaves ENN Energy listed as China gas consolidation stalls
Read how ENN Energy’s failed $11.6bn takeover reshapes 2688 stock sentiment, China gas consolidation and ENN Natural Gas strategy.
Akeso gumokimab approval strengthens China biologics push as psoriasis market heats up
Find out how Akeso’s gumokimab approval could reshape China’s psoriasis biologics market and boost its autoimmune drug strategy.
Could Snom D895M strengthen VTech Holdings’ enterprise IP communication strategy?
Find out how Snom D895M could reshape enterprise IP communication strategy for VTech Holdings and professional VoIP channel partners today!
Lenovo Group stock nears 52-week high as AI revenue powers record FY2025/26 results
Lenovo Group posted record FY2025/26 revenue as AI servers, PCs and services accelerated. Find out what this means for investors today!
Pony bets on NVIDIA DRIVE Hyperion to turn robotaxi compute into a commercial moat
Robotaxis need scale, but scale needs cheaper compute. Pony.ai’s NVIDIA platform tests whether autonomy can finally move from pilots to profits.
Antengene unveils three pipeline programs at AACR 2026 as AnTenGager platform expands beyond UCB deal
Antengene (SEHK: 6996.HK) presents ATG-125, ATG-106, and ATG-112 preclinical data at AACR 2026. Read what the results mean for its pipeline strategy.
Biocytogen just stacked two cancer bets in three days. Is its platform strategy starting to compound?
Biocytogen’s NEOK002 IND clearance and Moonlight Bio deal highlight a platform-led oncology strategy. Read what it means for growth and sentiment.
Insilico Medicine just doubled down on CNS with Tenacia. Here’s why that matters now.
Insilico Medicine has expanded its Tenacia CNS partnership in a deal worth up to $94.75 million. Read what it signals for AI drug discovery now.
Can Insilico Medicine’s PandaClaw agentic AI platform accelerate pharma software licensing revenue growth in 2026?
Insilico Medicine launches PandaClaw, an agentic AI tool that lets biologists run autonomous multi-omics drug discovery analysis. Read what it means for pharma.